In the study that spent two years tracking 4, 162 patients who had already survived a severe heart attack, those on high-dose Lipitor were 16% less likely to die or have heart attacks than those on standard-dose Pravachol.

FORBES: Pills for Everyone!

In November, NICE denied payment for a higher-than-standard dose of Glivec (Gleevec in the U.S.) for gastrointestinal stromal tumors, although some patients (14%, according to the manufacturer of the drug) would benefit from the higher dosage.

FORBES: Comparative Effectiveness: Hope Or Hype?